患者来源上皮细胞类器官可模拟子宫内膜异位症各亚型的表型复杂性
本研究从23例手术患者的28份子宫内膜异位症组织标本建立类器官,评估不同手术表型及激素治疗对建系成功率与形态的影响。结果显示总体78.6%标本形成三维结构,冷冻保存后53.6%存活;采集标本时接受激素治疗者建系成功率显著降低(3/13,23.1% vs 12/15,80.0%,P=0.003)。
要点
- 子宫内膜异位症类器官可在所有主要手术表型中建立,但成功率不同:卵巢子宫内膜瘤71.4%、深部浸润型63.6%、浅表腹膜型30%。
- 采集标本时接受激素治疗者类器官建系成功率显著低于未治疗者(23.1% vs 80.0%,P=0.003)。
- 浅表腹膜型和深部浸润型来源类器官保留孕激素受体表达(7/7,100%),卵巢子宫内膜瘤来源者则明显降低(5例中4例)。
核心结论
- 子宫内膜异位症类器官可在所有主要手术表型中建立,但效率不一;采集标本时接受激素治疗显著降低建系成功率。
研究设计与样本
- 研究纳入23例接受手术患者的28份子宫内膜异位症组织标本,包括深部浸润型、卵巢子宫内膜瘤和浅表腹膜型。
- 标本采用已验证的低Wnt培养系统建立类器官,并评估建系、传代和冷冻保存各阶段。
- 通过显微镜、免疫组化和定量形态学分析评估类器官活力、形态、激素受体表达和细胞组成。
主要发现
- 总体22/28(78.6%)份标本建立三维结构,冷冻保存后15/28(53.6%)保持存活。
- 建系成功率因表型而异:卵巢子宫内膜瘤71.4%、深部浸润型63.6%、浅表腹膜型30%。
- 浅表腹膜型和深部浸润型来源类器官保留孕激素受体表达(7/7,100%),卵巢子宫内膜瘤来源类器官则显著降低(5例中4例)。
- 接受激素治疗患者的标本较小(P=0.038),且类器官建系成功率降低(3/13,23.1% vs 12/15,80.0%,P=0.003)。
- 类器官呈现与疾病表型相关的不同形态模式。
临床怎么用
- 作者认为这些类器官模型为研究亚型特异性子宫内膜异位症生物学(包括激素抵抗机制)提供了有前景的平台,并可能有助于个体化治疗开发。
- 作者指出激素治疗对类器官活力的影响强调在临床前模型中需考虑临床背景。
局限性
- 统一的培养条件可能限制某些亚型的生长。
- 体外类器官模型可能无法完全代表体内组织的复杂性。
- 样本量较小。
- 合并同一患者的组织可能掩盖患者内异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can patient-derived organoid models be reliably established from diverse surgical phenotypes of endometriosis, and how do clinical factors such as hormonal treatment affect their growth success and morphology? SUMMARY ANSWER: Endometriosis organoids can be established across all major surgical phenotypes with variable efficiency, and hormonal treatment at the time of biospecimen collection significantly reduces organoid establishment success. WHAT IS KNOWN ALREADY: Organoid cultures have been developed from eutopic endometrium and select endometriosis tissue biospecimens previously, but their feasibility as pre-clinical models of endometriosis across diverse tissue types and clinical presentations remains unclear. STUDY DESIGN, SIZE, DURATION: Twenty-eight endometriosis tissue biospecimens were obtained from 23 patients undergoing surgery, with organoid cultures assessed through successive stages of establishment, passage, and cryopreservation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometriosis biospecimens, including deep infiltrating endometriosis (DIE), ovarian endometrioma (OMA), and superficial peritoneal (SUP) biospecimens, were processed into organoid cultures using a validated low-Wnt culture system. Organoid viability, morphology, hormone receptor expression, and cellular composition were evaluated by microscopy, immunohistochemistry, and quantitative morphometric analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 22/28 (78.6%) biospecimens established 3-dimensional structures, with 15/28 (53.6%) remaining viable after cryopreservation. Establishment success differed by phenotype (OMA 71.4%, DIE 63.6%, SUP 30%). Progesterone receptor expression was retained in SUP and DIE-derived organoids (7/7, 100%), while OMA-derived organoids showed substantial reductions (4/5 cases). Biospecimens from patients receiving hormonal treatment were smaller (P = 0.038) and had reduced organoid establishment success (3/13, 23.1% vs 12/15, 80.0%, P = 0.003). Organoids exhibited distinct morphological patterns correlating with disease phenotype. LIMITATIONS, REASONS FOR CAUTION: Uniform culture conditions may limit growth of certain subtypes, and the in vitro organoid models may not fully represent in vivo tissue complexity. Sample sizes were modest, and pooling tissues from the same patient could mask intra-patient heterogeneity. WIDER IMPLICATIONS OF THE FINDINGS: These organoid models offer a promising platform for studying subtype-specific endometriosis biology, including hormone resistance mechanisms, and could inform personalized therapeutic development. The impact of hormonal treatment on organoid viability underscores the need to consider clinical context in pre-clinical models of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Endometriosis Clinical and Scientific Trials (NECST) Network, funded by the Australian Government Department of Health and Aged Care (Grant 4-I66SNMA), and by a research grant from Endometriosis Australia to C.E.F., D.L., and J.A.A. K.G. is supported by an Australian Government Research Training Program Scholarship and a NECST Network Top-Up Scholarship, which did not influence the conduct or outcomes of this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. J.A.A. has received consulting fees from Hologic, Gedeon Richter, and BD, personal payments from Hologic, Bayer, Organon, and Gedeon Richter, travel support from Gedeon Richter, and participated on data safety monitoring advisory boards for Hologic and Gideon Richter. He was the former chair of the Australian Endometriosis Guideline Committee and is the Co-Editor-in-Chief of the Journal of Minimally Invasive Gynaecology. All other authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Gunther K, Liu D, Cortesi M, et al. Patient-derived epithelial cell organoids mimic the phenotypic complexity of endometriosis subtypes. Hum Reprod. 2026. PMID: 41298340. doi:10.1093/humrep/deaf230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。